Aerie Pharmaceuticals, Inc. (AERI) |
|
15.25 0 (0%)
|
11-18 16:00 |
|
Open: |
15.24 |
Pre. Close: |
15.25 |
|
High:
|
15.25 |
Low:
|
15.24 |
|
Volume:
|
1,215,184 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-12-09 4:20:13 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 17.81 One year: 20.8 |
| Support: |
Support1: 15.2 Support2: 15.17 |
| Resistance: |
Resistance1: 15.25 Resistance2: 17.81 |
| Pivot: |
15.23  |
| Moving Average: |
MA(5): 15.24 MA(20): 15.22
MA(100): 12.91 MA(250): 9.7 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 93.3 %D(3): 89.6 |
| RSI: |
RSI(14): 68.3 |
| 52-week: |
High: 15.36 Low: 4.8 |
| Average Vol(K): |
3-Month: 995 (K) 10-Days: 637 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AERI ] has closed below upper band by 9.1%. Bollinger Bands are 97.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
15.29 - 15.36 |
15.36 - 15.42 |
|
Low:
|
15.03 - 15.13 |
15.13 - 15.22 |
|
Close:
|
15.1 - 15.26 |
15.26 - 15.39 |
|
Company Description |
|
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina. |
Headline News |
Tue, 22 Nov 2022
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc ... - Business Wire
Tue, 22 Nov 2022
Alcon Completes Acquisition of Aerie Pharmaceuticals - citybiz
Thu, 03 Nov 2022
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results - Business Wire
Mon, 22 Aug 2022
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its ... - Business Wire
Thu, 04 Aug 2022
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial ... - Business Wire
Mon, 01 Aug 2022
Aerie Pharmaceuticals Announces First Participant Dosed in the ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
49 (M) |
| Shares Float |
44 (M) |
|
% Held by Insiders
|
1.7 (%) |
|
% Held by Institutions
|
103 (%) |
|
Shares Short
|
1,520 (K) |
|
Shares Short P.Month
|
1,600 (K) |
Stock Financials |
|
EPS
|
-1.48 |
|
EPS Est Next Qtl
|
-0.7 |
|
EPS Est This Year
|
-2.59 |
|
EPS Est Next Year
|
-2.18 |
|
Book Value (p.s.)
|
-3.32 |
|
Profit Margin (%)
|
-17.1 |
|
Operating Margin (%)
|
-12.5 |
|
Return on Assets (ttm)
|
-4.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
23.2 |
|
Gross Profit (p.s.)
|
3.38 |
|
Sales Per Share
|
4.32 |
|
EBITDA (p.s.)
|
-0.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
7 (M) |
|
Levered Free Cash Flow
|
2 (M) |
Stock Valuations |
|
PE Ratio
|
-10.38 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-4.6 |
|
Price to Sales
|
3.52 |
|
Price to Cash Flow
|
105.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
